| Clinical data | |
|---|---|
| Trade names | Nulojix |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a606016 |
| License data |
|
| Pregnancy category |
|
| Routes of administration | Intravenous |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| (verify) | |
Belatacept, sold under the brand name Nulojix, is a fusion protein composed of the Fc fragment of a human IgG1 immunoglobulin linked to the extracellular domain of CTLA-4,[1] which is a molecule crucial in the regulation of T cell costimulation, selectively blocking the process of T-cell activation. It is intended to provide extended graft and transplant[2] survival while limiting the toxicity generated by standard immune suppressing regimens, such as calcineurin inhibitors. It differs from abatacept (Orencia) by only two amino acids.
Belatacept was developed by Bristol-Myers-Squibb and approved by the U.S. Food and Drug Administration (FDA) on June 15, 2011.[3]
References
- ^ "Healthvalue.net: CTLA-4 Strategies". Archived from the original on 5 December 2008. Retrieved 2008-10-24.
- ^ Vincenti F, Rostaing L, Grinyo J, Rice K, Steinberg S, Gaite L, et al. (January 2016). "Belatacept and Long-Term Outcomes in Kidney Transplantation". The New England Journal of Medicine. 374 (4): 333–43. doi:10.1056/NEJMoa1506027. PMID 26816011.
- ^ "FDA approves Nulojix for kidney transplant patients" (Press release). U.S. Food and Drug Administration. 2011-06-15. Archived from the original on 19 June 2011. Retrieved 2011-06-16.
External links
- "Belatacept". Drug Information Portal. U.S. National Library of Medicine.